uniQure (NASDAQ:QURE) Price Target Raised to $20.00

uniQure (NASDAQ:QURE) had its price target hoisted by Royal Bank of Canada from $14.00 to $20.00 in a report released on Wednesday,Benzinga reports. Royal Bank of Canada currently has an outperform rating on the biotechnology company’s stock.

A number of other research firms have also weighed in on QURE. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of uniQure in a report on Tuesday. Cantor Fitzgerald upped their price target on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday. StockNews.com raised uniQure to a “sell” rating in a research note on Wednesday. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and upped their target price for the stock from $20.00 to $52.00 in a research note on Tuesday. Finally, The Goldman Sachs Group dropped their price target on uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.14.

uniQure Price Performance

uniQure stock opened at $15.40 on Wednesday. The firm has a market capitalization of $750.60 million, a P/E ratio of -3.10 and a beta of 0.89. uniQure has a one year low of $3.73 and a one year high of $17.39. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The business has a fifty day moving average price of $6.85 and a 200-day moving average price of $6.28.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. As a group, equities research analysts forecast that uniQure will post -3.81 EPS for the current year.

Insider Activity at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 4.74% of the stock is currently owned by insiders.

Institutional Investors Weigh In On uniQure

A number of institutional investors have recently made changes to their positions in the business. abrdn plc lifted its stake in uniQure by 381.7% in the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after purchasing an additional 1,528,581 shares during the last quarter. Franklin Resources Inc. purchased a new position in shares of uniQure in the third quarter worth about $7,360,000. Vanguard Group Inc. lifted its stake in shares of uniQure by 11.4% in the 1st quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock valued at $5,577,000 after acquiring an additional 109,740 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after acquiring an additional 752,889 shares during the period. Finally, Privium Fund Management B.V. grew its position in uniQure by 16.3% during the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock worth $3,672,000 after acquiring an additional 104,500 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.